Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.


We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Reaxense helps in synthesizing and delivering these compounds.


Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.


We employ our advanced, specialised process to create targeted libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.


Several key aspects differentiate our library:


  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.

  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.

  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.

  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.


PARTNER
Receptor.AI
 
UPACC
Q6MZZ7

UPID:
CAN13_HUMAN

ALTERNATIVE NAMES:
Calcium-activated neutral proteinase 13

ALTERNATIVE UPACC:
Q6MZZ7; Q17RF0; Q580X1; Q8TE80

BACKGROUND:
Calpain-13, alternatively named Calcium-activated neutral proteinase 13, is identified as a probable non-lysosomal thiol-protease. It is a part of the extensive calpain family, proteins known for their role in calcium-dependent cellular processes. The distinct characteristics and functions of Calpain-13 within this family offer a promising avenue for detailed scientific exploration.

THERAPEUTIC SIGNIFICANCE:
Exploring the functionalities of Calpain-13 holds the promise of uncovering new therapeutic avenues. Given its critical role in modulating calcium signaling, insights into Calpain-13 could lead to breakthroughs in treating conditions associated with calcium dysregulation.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.